Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
Link to record
Permanent link

Direct link
Publications (10 of 99) Show all publications
Kuylenstierna, A., Romare Strandh, M., Melzi, G., Lindman, H., Hellstadius, Y., Sköld, C., . . . Wikman, A. (2026). Affect-focused psychodynamic psychotherapy for mothers diagnosed with cancer: A feasibility study. Internet Interventions, 43, Article ID 100916.
Open this publication in new window or tab >>Affect-focused psychodynamic psychotherapy for mothers diagnosed with cancer: A feasibility study
Show others...
2026 (English)In: Internet Interventions, ISSN 2214-7829, Vol. 43, article id 100916Article in journal (Refereed) Published
Abstract [en]

Background: Parents with cancer face elevated psychological distress, often exacerbated by parenting responsibilities. Affect-Focused Psychodynamic Therapy (AFPT) has shown efficacy in improving emotion regulation, psychological well-being and self-compassion, but its feasibility and preliminary effect in this population remains unexplored.

Objective: The aim of this study was to evaluate the feasibility, acceptability, safety, and preliminary effects on symptoms of depression and anxiety, of AFPT delivered via videoconferencing for parents with cancer.

Methods: The intervention consisted of 10 sessions of AFPT, specifically affect phobia therapy. Qualitative data were collected through post-intervention interviews and analysed using inductive content analysis. Quantitative data were collected through self-report questionnaires at pre-intervention, post-intervention, and at 6-month follow-up measuring symptoms of depression and anxiety (primary outcome), parenting concerns, emotion regulation, self-efficacy, adaptive affective functioning, closeness in the family and self-rated health. Quantitative data were analysed using dependent-samples t-tests, with Cohen's d for effect sizes, and McNemar tests.

Results: Fifteen mothers with cancer participated in the study. Results demonstrated efficient recruitment, acceptable study procedures, complete retention, and a relevant and beneficial intervention rated 8.4/10 in helpfulness. Moreover, findings showed significant reductions in symptoms of depression (Cohen's d = 1.29) and of anxiety (Cohen's d = 1.06) from pre- to post-intervention, maintained at 6-month follow-up, together with improvements in a majority of the secondary outcomes.

Conclusions: Videoconferencing AFPT appears feasible, acceptable, and safe to use for mothers with cancer, with promising preliminary effects in reducing psychological distress. These findings support further evaluation of the intervention to determine its efficacy in this population using a randomized controlled trial.

Place, publisher, year, edition, pages
Elsevier, 2026
Keywords
neoplasms, parenting, psychological interventions, psychodynamic therapy, affect-focused psychotherapy
National Category
Psychiatry Applied Psychology
Identifiers
urn:nbn:se:uu:diva-582052 (URN)10.1016/j.invent.2026.100916 (DOI)001697960800001 ()41755902 (PubMedID)2-s2.0-105030296428 (Scopus ID)
Funder
Bröstcancerförbundet, F2024-0023
Available from: 2026-03-13 Created: 2026-03-13 Last updated: 2026-03-13Bibliographically approved
Schiza, A., Fountzilas, E., Biganzoli, L., Digkas, E., Fjermeros, K., Geisler, J., . . . Othman, M. (2026). CDK4/6 inhibitor dose patterns among older patients with metastatic breast cancer: A multinational survey study [Letter to the editor]. Journal of Geriatric Oncology, 17(7), Article ID 103068.
Open this publication in new window or tab >>CDK4/6 inhibitor dose patterns among older patients with metastatic breast cancer: A multinational survey study
Show others...
2026 (English)In: Journal of Geriatric Oncology, ISSN 1879-4068, E-ISSN 1879-4076, Vol. 17, no 7, article id 103068Article in journal, Letter (Other academic) Published
Place, publisher, year, edition, pages
Elsevier, 2026
Keywords
CDK4/6 inhibitors, Geriatric oncology, Metastatic breast cancer, Prescribing practices, Multinational survey, Dose reduction
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-595290 (URN)10.1016/j.jgo.2026.103068 (DOI)001825791800001 ()42447829 (PubMedID)2-s2.0-105044484242 (Scopus ID)
Funder
EU, Horizon 2020, 101104589
Available from: 2026-08-13 Created: 2026-08-13 Last updated: 2026-08-13Bibliographically approved
Sahin, U., Schmidt, M., Derhovanessian, E., Cortini, A., Vogler, I., Omokoko, T., . . . Türeci, O. (2026). Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC. Nature, 651(8107), 1088-1096
Open this publication in new window or tab >>Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC
Show others...
2026 (English)In: Nature, ISSN 0028-0836, E-ISSN 1476-4687, Vol. 651, no 8107, p. 1088-1096Article in journal (Refereed) Published
Abstract [en]

Triple-negative breast cancer (TNBC) is frequently associated with metastatic relapse, even at an early stage1. Here we assessed an individualized neoantigen mRNA vaccine in 14 patients with TNBC following surgery and after neoadjuvant or adjuvant therapy. In peripheral blood of nearly all patients, high-magnitude, vaccine-induced, mostly de novo T cell responses to multiple neoantigens were detected that remained functional for several years. Characterization of individual patients revealed that a large proportion of these T cells developed into two subsets: a late-differentiated phenotype with markers indicative of 'ready-to-act' cytotoxic effector T cells, and T cells with a stem cell-like memory phenotype. Eleven patients remained relapse-free for up to six years post-vaccination. Recurrence occurred in three patients: the individual with the weakest vaccine-induced T cell response relapsed, but achieved complete remission on subsequent anti-PD-1 therapy; another patient had a tumour with low major histocompatibility complex (MHC) class I expression with MHC class I-deficient cells growing out under vaccination; and the third patient was BRCA-positive and had a recurrence from a genetically distinct primary tumour. These findings demonstrate the feasibility of individualized RNA vaccines in TNBC, document persistence of vaccine-induced, functional neoantigen-specific T cells and provide insights into possible immune escape mechanisms that will guide future approaches.

Place, publisher, year, edition, pages
Springer Nature, 2026
National Category
Cancer and Oncology Immunology in the Medical Area
Identifiers
urn:nbn:se:uu:diva-589142 (URN)10.1038/s41586-025-10004-2 (DOI)001693995700001 ()41708868 (PubMedID)2-s2.0-105030528973 (Scopus ID)
Funder
EU, FP7, Seventh Framework Programme, 601939
Available from: 2026-06-25 Created: 2026-06-25 Last updated: 2026-06-25Bibliographically approved
Cazzaniga, M. E., Costa, L., Freyer, G., Gligorov, J., Lindman, H., Wysocki, P. J. & Bartsch, R. (2026). Risk Factors for Disease Recurrence in Patients with HER2+ Early Breast Cancer and Implications for Therapy: A Narrative Review. Oncology and Therapy, 14(1), 95-112
Open this publication in new window or tab >>Risk Factors for Disease Recurrence in Patients with HER2+ Early Breast Cancer and Implications for Therapy: A Narrative Review
Show others...
2026 (English)In: Oncology and Therapy, ISSN 2366-1070, E-ISSN 2366-1089, Vol. 14, no 1, p. 95-112Article in journal (Refereed) Published
Abstract [en]

Human epidermal growth factor receptor 2 (HER2) overexpression or amplification of the human ERBB2 oncogene occurs in approximately one-fifth of breast cancers and, of these, two-thirds are hormone receptor (HR)-positive (HR+). The introduction of HER2-targeted therapies in recent years has significantly improved survival outcomes in patients with this tumor subtype. However, disease recurrence risk is 10–30% at 5 years with a different pattern between patients with HER2+/HR+ and HER2+/HR-negative (HR−) early breast cancer, with HR+ patients having a lower risk than those with HR− disease in the first 5 years, but a slightly higher risk at 5–10 years post-surgery. This highlights a crucial need to explore the underlying mechanisms for these differences to address specific treatment needs and to optimize systemic adjuvant treatment outcomes. Therefore, this narrative review provides an overview of published data regarding the recognized factors and ongoing challenges associated with the risk of relapse in women with HER2+ early breast cancer and proposes potential adjuvant treatment strategies to minimize risk of recurrence in high-risk patients.

Place, publisher, year, edition, pages
Springer Nature, 2026
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-574773 (URN)10.1007/s40487-025-00398-4 (DOI)001609897100001 ()41205024 (PubMedID)2-s2.0-105021227610 (Scopus ID)
Available from: 2026-01-07 Created: 2026-01-07 Last updated: 2026-08-14Bibliographically approved
Nyback, S., Sundström Poromaa, I., Lindman, H., Hirschberg, A. L., Kallner, H. K., Wikman, A. & Kunovac Kallak, T. (2026). Vaginal tamoxifen - A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen. European Journal of Cancer, 236, Article ID 116261.
Open this publication in new window or tab >>Vaginal tamoxifen - A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen
Show others...
2026 (English)In: European Journal of Cancer, ISSN 0959-8049, E-ISSN 1879-0852, Vol. 236, article id 116261Article in journal (Refereed) Published
Abstract [en]

Background: There is a great need for non-estrogenic treatment of vulvovaginal atrophy (VVA) symptoms affecting sexual function and quality of life. Women with breast cancer on anti-estrogenic therapy are particularly vulnerable and in need of help. The primary aim of this proof-of-concept trial was to evaluate the efficacy of vaginal tamoxifen in reducing the most troublesome VVA symptom.

Methods: In this randomized, double blind, placebo-controlled study, 115 postmenopausal women, with or without breast cancer, were randomized to 20 mg vaginal tamoxifen once weekly or placebo (1:1). Follow-up after one and three-months of treatment, included self-reported VVA symptoms on the Endocrine Symptom Subscale of FACT-B, and gynecologic exams for VVA score and measurement of vaginal pH and endometrial thickness.

Findings: After three months, 37 (68.6 %) of women on vaginal tamoxifen reported their most troublesome VVA symptom to be mild or not present at all, whereas corresponding number in the placebo group was 5 (9.1 %), p < 0.001. Expressed as odds, women on vaginal tamoxifen were more likely to report no or minor symptoms after three-months, OR 21.76 (95 % CI 7.36 - 64.3). The improvement in self-reported outcomes was accompanied by improvements in VVA scores and vaginal pH, p <0.001.

Interpretation: This study has demonstrated that more than two-thirds of the women on vaginal tamoxifen improved in their most troublesome VVA symptom. This is likely due to a tamoxifen-induced estrogen agonistic effects in vagina in a low-estrogen environment. While findings are promising, further studies on improved vaginal administration and endometrial safety concerns are needed.

Place, publisher, year, edition, pages
Elsevier, 2026
Keywords
Breast cancer, Aromatase inhibitors, Vulvovaginal atrophy, Pain during sex, Vaginal tamoxifen
National Category
Cancer and Oncology Gynaecology, Obstetrics and Reproductive Medicine
Identifiers
urn:nbn:se:uu:diva-581720 (URN)10.1016/j.ejca.2026.116261 (DOI)001685317500001 ()41643515 (PubMedID)2-s2.0-105029240208 (Scopus ID)
Funder
Swedish Cancer SocietyBröstcancerförbundetMagnus Bergvall FoundationErik, Karin och Gösta Selanders Foundation
Available from: 2026-03-10 Created: 2026-03-10 Last updated: 2026-03-10Bibliographically approved
Álvez, M. B., Bergström, S., Kenrick, J., Johansson, E., Åberg, M., Akyildiz, M., . . . Uhlén, M. (2025). A human pan-disease blood atlas of the circulating proteome. Science, 390(6779), Article ID eadx2678.
Open this publication in new window or tab >>A human pan-disease blood atlas of the circulating proteome
Show others...
2025 (English)In: Science, ISSN 0036-8075, E-ISSN 1095-9203, Vol. 390, no 6779, article id eadx2678Article in journal (Refereed) Published
Abstract [en]

The human blood proteome provides a holistic readout of health states through the assessment of thousands of circulating proteins. Here, we present a pan-disease resource to enable the study of diverse disease phenotypes within a harmonized proteomics dataset. By profiling protein concentrations across 59 diseases and healthy cohorts, we identified proteins associated with age, sex, and BMI, as well as disease-specific signatures. This study highlights shared and distinct protein patterns across conditions, demonstrating the power of a unified proteomics approach to uncover biological insights. The dataset, covering 8,262 individuals and up to 5,416 proteins, serves as an online resource for exploring disease-specific protein profiles and advancing precision medicine research.

Place, publisher, year, edition, pages
American Association for the Advancement of Science (AAAS), 2025
National Category
Medical Biotechnology
Identifiers
urn:nbn:se:uu:diva-569491 (URN)10.1126/science.adx2678 (DOI)001643421200001 ()41066540 (PubMedID)2-s2.0-105025246161 (Scopus ID)
Available from: 2025-10-14 Created: 2025-10-14 Last updated: 2026-10-30Bibliographically approved
Olsson, E., Lindman, H., Digkas, E., Thurfjell, V., Ali, H. M., Kruger, U., . . . Valachis, A. (2025). Genomic characterization and molecular predictive biomarkers for chemotherapy in patients with metastatic triple-negative breast cancer treated in a real-world setting. The Breast, 79, Article ID 103874.
Open this publication in new window or tab >>Genomic characterization and molecular predictive biomarkers for chemotherapy in patients with metastatic triple-negative breast cancer treated in a real-world setting
Show others...
2025 (English)In: The Breast, ISSN 0960-9776, E-ISSN 1532-3080, Vol. 79, article id 103874Article in journal (Refereed) Published
Abstract [en]

Purpose: We aimed to characterize genomic alterations with potential prognostic or predictive significance in patients with metastatic triple-negative breast cancer (mTNBC) treated with chemotherapy in a real-world setting. Patients and methods: Next-generation sequencing with FoundationOne (R) CDx was conducted primarily on primary tumor tissue from 112 consecutive patients with mTNBC. Genomic alterations were subdivided into canonical oncogenic pathways and noted for their involvement in homologous recombination deficiency (HRD). Altered genes and pathways were correlated with overall survival (OS) and evaluated regarding their association with real-world progression-free survival (rwPFS) in patients treated with different chemotherapy agents. Occurrence of alterations were compared between patients with exceptional response and rapid progression to chemotherapy. Results: After exclusion due to insufficient tumor tissue or clinical data, material from 97 patients was analyzed. The most frequently altered genes were TP53 (82 %), RAD21 (25 %) and PIK3CA (23 %). Altogether, 26 % of patients had an alteration leading to HRD. None of the analyzed alterations were associated with OS. Variants leading to HRD were associated with a prolonged rwPFS in patients treated with platinum-based chemotherapy in the first line setting (hazard ratio [HR], 0.31 [95 % CI: 0.12-0.84]). Exceptional responders more often exhibited alterations in the MYC and RAS/RTK pathways compared to rapid progressors. Conclusions: Patients with tumor alterations in HRD-related genes seem to define subgroups that respond favorably to platinum-based chemotherapy. Further research into the genomic landscape of tumors from patients with rapid progression or exceptional response to different treatment strategies can provide insights into mechanisms of resistance and identify predictive biomarkers.

Place, publisher, year, edition, pages
Elsevier, 2025
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-556836 (URN)10.1016/j.breast.2025.103874 (DOI)001427504700001 ()39778370 (PubMedID)2-s2.0-85214103461 (Scopus ID)
Available from: 2025-05-28 Created: 2025-05-28 Last updated: 2025-08-28Bibliographically approved
Palmer, S., Valachis, A., Lindman, H., Smith, D. R., Wickberg, A., Killander, F., . . . Villman, K. (2025). Omission of postoperative radiotherapy after breast-conserving surgery in low-risk breast cancer. Journal of the National Cancer Institute, 117(6), 1125-1133
Open this publication in new window or tab >>Omission of postoperative radiotherapy after breast-conserving surgery in low-risk breast cancer
Show others...
2025 (English)In: Journal of the National Cancer Institute, ISSN 0027-8874, E-ISSN 1460-2105, Vol. 117, no 6, p. 1125-1133Article in journal (Refereed) Published
Abstract [en]

Background This prospective cohort study aimed to assess whether postoperative radiotherapy could safely be omitted in women aged 65 years and older with low-risk, estrogen receptor-positive T1N0 breast cancer treated with breast-conserving surgery and adjuvant endocrine therapy.

Methods Eligible patients were women aged 65 years and older with unifocal, nonlobular, grade 1 or 2, estrogen receptor-positive, pT1N0 breast cancer treated with breast-conserving surgery and endocrine therapy for 5 years. Patients were followed up with mammography at least annually for 10 years. The primary endpoint was local recurrence. Secondary endpoints were contralateral breast cancer, recurrence-free survival, and overall survival.

Results The final study cohort included 601 patients with a median age of 71 years (range = 65-90 years) and a median tumor size of 11 mm (range = 3-20 mm). Median follow-up time was 119 months (interquartile range = 103-121 months). The cumulative incidence of local recurrence was 1.5% (95% confidence interval [CI] = 0.8% to 2.8%) and 5.5% (95% CI = 3.8% to 7.6%) at 5 and 10 years, respectively. The cumulative incidence of contralateral breast cancer was 1.7% (95% CI = 0.9% to 3.0%) at 5 years and 4.5% (95% CI = 3.0% to 6.6%) at 10 years. The overall survival rate at 10 years was 83.1% (95% CI = 80.8% to 85.4%). In total, 3 (0.5%) patients died because of breast cancer.

Conclusion Our results support the possibility to omit radiotherapy after breast-conserving surgery in a well-defined subgroup of women aged 65 years and older with low-risk, estrogen receptor-positive, pT1N0 breast cancer receiving adjuvant endocrine therapy.

Place, publisher, year, edition, pages
Oxford University Press, 2025
Keywords
follow-up prospective studies breast cancer endocrine therapy breast conserving surgery postoperative radiotherapy breast cancer, contralateral estrogen receptor positive tumor size hormonal therapy, adjuvant
National Category
Cancer and Oncology Surgery
Identifiers
urn:nbn:se:uu:diva-569568 (URN)10.1093/jnci/djae315 (DOI)001466774600001 ()39656805 (PubMedID)2-s2.0-105008251808 (Scopus ID)
Funder
Örebro University, OLL-589691
Available from: 2025-10-27 Created: 2025-10-27 Last updated: 2025-10-30Bibliographically approved
Kjällquist, U., Tsiknakis, N., Acs, B., Margolin, S., Kessler, L. E., Levy, S., . . . Matikas, A. (2025). Optimization of guidelines for Risk Of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter study. The Breast, 82, Article ID 104489.
Open this publication in new window or tab >>Optimization of guidelines for Risk Of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter study
Show others...
2025 (English)In: The Breast, ISSN 0960-9776, E-ISSN 1532-3080, Vol. 82, article id 104489Article in journal (Refereed) Published
Abstract [en]

Purpose: Gene expression profiles are used for decision making in the adjuvant setting in hormone receptorpositive, HER2-negative (HR+/HER2-) breast cancer. While algorithms to optimize testing exist for RS/Oncotype Dx, no such efforts have focused on ROR/Prosigna. This study aims to enhance pre-selection of patients for testing using machine learning. Methods: We included 348 postmenopausal women with resected HR+/HER2-node-negative breast cancer tested with ROR/Prosigna across four Swedish regions. We developed a machine learning model using simple prognostic factors (size, progesterone receptor expression, grade, and Ki67) to predict ROR/Prosigna output and compared the performance regarding over- and undertreatment with commonly employed risk stratification schemes. Results: Previous classifications resulted in significant undertreatment or large intermediate groups needing gene expression profiling. The machine learning model achieved AUC under ROC of 0.77 in training and 0.83 in validation cohorts for prediction of indication for adjuvant chemotherapy according to ROR/Prosigna. By setting and validating upper and lower cut-offs corresponding to low, intermediate and high-risk disease, we improved risk stratification accuracy and reduced the proportion of patients needing ROR/Prosigna testing compared to current risk stratification. Conclusion: Machine learning algorithms can enhance patient selection for gene expression profiling, though further external validation is needed.

Place, publisher, year, edition, pages
Elsevier, 2025
Keywords
Adjuvant, Breast cancer, Machine learning, Prosigna, Risk of recurrence
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-557864 (URN)10.1016/j.breast.2025.104489 (DOI)001492946000001 ()40347583 (PubMedID)2-s2.0-105004588252 (Scopus ID)
Funder
Swedish Cancer SocietySwedish Research Council
Available from: 2025-06-03 Created: 2025-06-03 Last updated: 2025-12-01Bibliographically approved
Alhuseinalkhudhur, A., Lindman, H., Liss, P., Frejd, F., Feldwisch, J., Brun, N. C., . . . Sörensen, J. (2024). [68Ga]Ga-ABY-025 PET in HER2-positive breast cancer: Benefits and pitfalls in staging of axillary disease. Journal of Clinical Oncology, 42(16), Article ID 1035.
Open this publication in new window or tab >>[68Ga]Ga-ABY-025 PET in HER2-positive breast cancer: Benefits and pitfalls in staging of axillary disease
Show others...
2024 (English)In: Journal of Clinical Oncology, ISSN 0732-183X, E-ISSN 1527-7755, Vol. 42, no 16, article id 1035Article in journal (Refereed) Published
Abstract [en]

Background:

[68Ga]Ga-ABY-025 PET showed promising results in quantifying human epidermal growth factor receptor Type 2 (HER2) expression in breast cancer patients [1]. In this study we extend the findings from [68Ga]Ga-ABY-025 PET with data from both treatment-naïve patients and previously treated patients with recurrences, mimicking the clinical situation other sites might encounter when HER2-targeting imaging is made more widely available. The focus of this additional data analysis is on staging, potential pitfalls and changes in uptake patterns associated with previous treatments.

Methods:

[68Ga]Ga-ABY-025 PET and [18F]-FDG PET images from 50 women with biopsy confirmed HER2 positive breast cancer were examined. Each patient underwent both scans within 1 week. A follow-up [18F]-FDG PET was performed after 2 courses of HER2-targeted treatment to assess metabolic response.

Results:

Twelve out of 50 patients showed heterogeneous [68Ga]Ga-ABY-025 uptake. Three out of these 12 patients presented with a wider local spread that was only detectable using [68Ga]Ga-ABY-025 PET as distinct uptake in lymph nodes of 2-5 mm size. Based on the additional information from [68Ga] Ga-ABY-025 PET, restaging was evaluated in two of the three cases, both of which had lobular carcinoma, and resulted in modifications in treatment plans. Two patients who received COVID-19 vaccine closely before undergoing PET scans showed high uptake on [18F]-FDG PET in lymph nodes ipsilateral to the vaccine injection site, but not on [68Ga]Ga-ABY-025 PET. Additionally, the physiological [68Ga]Ga-ABY-025 uptake in thyroid gland and axillary sweat glands was inversely correlated with the number of previous treatments and was significantly more pronounced in treatment-naïve patients.

Conclusions:

[68Ga]Ga-ABY-025 PET provided additional information that, in conjunction with [18F]-FDG PET findings, might help in accurate staging, particularly in cases with very small lymph node metastases. It also helped reduce false positive results as [68Ga]Ga-ABY-025 uptake was so far not seen in any benign inflammatory lesions. Physiological uptake can be seen in thyroid and apocrine glandular tissues but gradually disappear with subsequent HER2-targeted therapies.

Clinical trial information: NCT03655353. Research Sponsor: Swedish Breast Cancer Association; Swedish Cancer Society; Roche AB Sweden; The Percy Falk Foundation. 

Place, publisher, year, edition, pages
Lippincott Williams and Wilkins, 2024
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-579624 (URN)10.1200/JCO.2024.42.16_suppl.1035 (DOI)2-s2.0-105023416760 (Scopus ID)
Available from: 2026-02-23 Created: 2026-02-23 Last updated: 2026-02-23Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0002-5871-268x

Search in DiVA

Show all publications